---- is really out of question. They are not going to find anything different. Getting the drug back on market with likely testing for reactions for new patients (if they cannot identify the source of reactions) is the only way forward, especially for a drug that has had an excellent safety profile for so long.
Healthy people die of tylenol liver toxicity, have they taken tylenol is off the market?
Omontys does not have an excellent safety profile. See the PEARL studies that proved Omontys unsafe for CKD patients not on dialysis. Those patients are the healthier ones compared to CKD dialysis patients. AFFY called the PEARL study result "inexplicable".